Lewis RT - Search Results

1

Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitors.

Thomson JL, Blackaby WP, Jennings AS, Goodacre SC, Pike A, Thomas S, Brown TA, Smith A, Pillai G, Street LJ, Lewis RT. Thomson JL, et al. Among authors: lewis rt. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2235-9. doi: 10.1016/j.bmcl.2009.02.102. Epub 2009 Feb 28. Bioorg Med Chem Lett. 2009. PMID: 19318248

2

Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

Jennings AS, Lewis RT, Russell MG, Hallett DJ, Street LJ, Castro JL, Atack JR, Cook SM, Lincoln R, Stanley J, Smith AJ, Reynolds DS, Sohal B, Pike A, Marshall GR, Wafford KA, Sheppard WF, Tye SJ. Jennings AS, et al. Among authors: lewis rt. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1477-80. doi: 10.1016/j.bmcl.2005.12.044. Epub 2006 Jan 4. Bioorg Med Chem Lett. 2006. PMID: 16386900

3

Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.

Goodacre SC, Street LJ, Hallett DJ, Crawforth JM, Kelly S, Owens AP, Blackaby WP, Lewis RT, Stanley J, Smith AJ, Ferris P, Sohal B, Cook SM, Pike A, Brown N, Wafford KA, Marshall G, Castro JL, Atack JR. Goodacre SC, et al. Among authors: lewis rt. J Med Chem. 2006 Jan 12;49(1):35-8. doi: 10.1021/jm051065l. J Med Chem. 2006. PMID: 16392789

4

Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.

Blackaby WP, Atack JR, Bromidge F, Castro JL, Goodacre SC, Hallett DJ, Lewis RT, Marshall GR, Pike A, Smith AJ, Street LJ, Tattersall DF, Wafford KA. Blackaby WP, et al. Among authors: lewis rt. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1175-9. doi: 10.1016/j.bmcl.2005.11.112. Epub 2006 Jan 6. Bioorg Med Chem Lett. 2006. PMID: 16406613

5

A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

Lewis RT, Blackaby WP, Blackburn T, Jennings AS, Pike A, Wilson RA, Hallett DJ, Cook SM, Ferris P, Marshall GR, Reynolds DS, Sheppard WF, Smith AJ, Sohal B, Stanley J, Tye SJ, Wafford KA, Atack JR. Lewis RT, et al. J Med Chem. 2006 Apr 20;49(8):2600-10. doi: 10.1021/jm051144x. J Med Chem. 2006. PMID: 16610803

6

Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1.

Blackaby WP, Lewis RT, Thomson JL, Jennings AS, Goodacre SC, Street LJ, MacLeod AM, Pike A, Wood S, Thomas S, Brown TA, Smith A, Pillai G, Almond S, Guscott MR, Burns HD, Eng W, Ryan C, Cook J, Hamill TG. Blackaby WP, et al. Among authors: lewis rt. ACS Med Chem Lett. 2010 Jun 25;1(7):350-4. doi: 10.1021/ml1001085. eCollection 2010 Oct 14. ACS Med Chem Lett. 2010. PMID: 24900218 Free PMC article.

7

Pyrazolopyridinones as functionally selective GABAA ligands.

Blackaby WP, Atack JR, Bromidge F, Lewis R, Russell MG, Smith A, Wafford K, McKernan RM, Street LJ, Castro JL. Blackaby WP, et al. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4998-5002. doi: 10.1016/j.bmcl.2005.08.006. Bioorg Med Chem Lett. 2005. PMID: 16153832

8

The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone.

Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS. Atack JR, et al. Among authors: lewis rt. Neuropharmacology. 2006 May;50(6):677-89. doi: 10.1016/j.neuropharm.2005.11.014. Epub 2006 Jan 20. Neuropharmacology. 2006. PMID: 16430927

9

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

Peterson EA, Boezio AA, Andrews PS, Boezio CM, Bush TL, Cheng AC, Choquette D, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Kim JL, Lewis RT, Liu J, Mullady EL, Potashman MH, Romero K, Shaffer PL, Stanton MK, Stellwagen JC, Teffera Y, Yi S, Cai T, La DS. Peterson EA, et al. Among authors: lewis rt. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4967-74. doi: 10.1016/j.bmcl.2012.06.033. Epub 2012 Jun 16. Bioorg Med Chem Lett. 2012. PMID: 22765895

10

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC. Bode CM, et al. Among authors: lewis rt. Bioorg Med Chem Lett. 2012 Jun 15;22(12):4089-93. doi: 10.1016/j.bmcl.2012.04.072. Epub 2012 Apr 25. Bioorg Med Chem Lett. 2012. PMID: 22595176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters